A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
Enrolling by invitation · NCT05441475 · Registry updated 2026-02-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Enrolling by invitation | Phase 2 | 2026-02-25 | NCT05441475 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Abbisko Therapeutics Co, Ltd | 22 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology | Hubei | China | 1 |